Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $12.40, but opened at $13.75. Adlai Nortye shares last traded at $13.75, with a volume of 27,872 shares trading hands.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Adlai Nortye in a report on Friday, January 12th.
View Our Latest Stock Report on ANL
Adlai Nortye Price Performance
Institutional Investors Weigh In On Adlai Nortye
A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its holdings in Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) by 128.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. 35.21% of the stock is currently owned by hedge funds and other institutional investors.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Charles Schwab Fortifies its Uptrend on EPS Beat
- How to Invest in the Best Canadian StocksĀ
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What Makes a Stock a Good Dividend Stock?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.